Blastemal predominant type Wilms tumor in Japan

Japan Children's Cancer Group

Tsugumichi Koshinaga, Tetsuya Takimoto, Hajime Okita, Yukichi Tanaka, Eisuke Inoue, Takaharu Oue, Miwako Nozaki, Kunihiko Tsuchiya, Masayuki Haruta, Yasuhiko Kaneko, Masahiro Fukuzawa

Research output: Contribution to journalArticle

Abstract

Background: Persistence of blastemal components after chemotherapy is a marker of poor outcome in Wilms tumor (WT). Recent reports from local Japanese areas have described pre-chemotherapy blastemal predominant type WT to also be a risk factor for relapse. The significance, however, of blastemal predominant WT remains to be evaluated in a larger study. This study retrospectively evaluated the prognostic significance of pre-chemotherapy blastemal predominant type WT in the Japan Wilms tumor Study (JWiTS) trials. Methods: The JWiTS trial (1996–2013) was a prospective, single-arm study. The outcomes of blastemal predominant type WT were retrospectively evaluated compared with non-blastemal type WT excluding anaplasia between 1996 and 2013. Relapse-free survival (RFS) and overall survival (OS) were estimated. Results: Of 319 primary renal tumors diagnosed by the central pathology review system, advanced stage of pre-chemotherapy blastemal predominant type WT (n = 53; 16.1%) occurred more frequently in older children than non-blastemal type WT (n = 225), and was especially frequent in female patients registered in the JWiTS trials. No significant difference in 10 years RFS and OS (78.8% vs 84.5; P = 0.201) or in 10 years RFS and OS (89.3% vs 93.5; P = 0.45) was seen between pre-chemotherapy blastemal predominant type and non-blastemal type WT. Conclusions: Relapse-free survival and OS are not significantly different between pre-chemotherapy blastemal predominant type and non-blastemal type WT.

Original languageEnglish
Pages (from-to)351-357
Number of pages7
JournalPediatrics International
Volume61
Issue number4
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

Wilms Tumor
Japan
Neoplasms
Survival
Drug Therapy
Recurrence
Anaplasia

Keywords

  • blastemal component
  • blastemal predominant type
  • pediatric
  • renal tumor
  • Wilms tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Koshinaga, T., Takimoto, T., Okita, H., Tanaka, Y., Inoue, E., Oue, T., ... Fukuzawa, M. (2019). Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group. Pediatrics International, 61(4), 351-357. https://doi.org/10.1111/ped.13811

Blastemal predominant type Wilms tumor in Japan : Japan Children's Cancer Group. / Koshinaga, Tsugumichi; Takimoto, Tetsuya; Okita, Hajime; Tanaka, Yukichi; Inoue, Eisuke; Oue, Takaharu; Nozaki, Miwako; Tsuchiya, Kunihiko; Haruta, Masayuki; Kaneko, Yasuhiko; Fukuzawa, Masahiro.

In: Pediatrics International, Vol. 61, No. 4, 01.04.2019, p. 351-357.

Research output: Contribution to journalArticle

Koshinaga, T, Takimoto, T, Okita, H, Tanaka, Y, Inoue, E, Oue, T, Nozaki, M, Tsuchiya, K, Haruta, M, Kaneko, Y & Fukuzawa, M 2019, 'Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group', Pediatrics International, vol. 61, no. 4, pp. 351-357. https://doi.org/10.1111/ped.13811
Koshinaga, Tsugumichi ; Takimoto, Tetsuya ; Okita, Hajime ; Tanaka, Yukichi ; Inoue, Eisuke ; Oue, Takaharu ; Nozaki, Miwako ; Tsuchiya, Kunihiko ; Haruta, Masayuki ; Kaneko, Yasuhiko ; Fukuzawa, Masahiro. / Blastemal predominant type Wilms tumor in Japan : Japan Children's Cancer Group. In: Pediatrics International. 2019 ; Vol. 61, No. 4. pp. 351-357.
@article{d1e2ecda732048cb9b352bf03f66ea9d,
title = "Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group",
abstract = "Background: Persistence of blastemal components after chemotherapy is a marker of poor outcome in Wilms tumor (WT). Recent reports from local Japanese areas have described pre-chemotherapy blastemal predominant type WT to also be a risk factor for relapse. The significance, however, of blastemal predominant WT remains to be evaluated in a larger study. This study retrospectively evaluated the prognostic significance of pre-chemotherapy blastemal predominant type WT in the Japan Wilms tumor Study (JWiTS) trials. Methods: The JWiTS trial (1996–2013) was a prospective, single-arm study. The outcomes of blastemal predominant type WT were retrospectively evaluated compared with non-blastemal type WT excluding anaplasia between 1996 and 2013. Relapse-free survival (RFS) and overall survival (OS) were estimated. Results: Of 319 primary renal tumors diagnosed by the central pathology review system, advanced stage of pre-chemotherapy blastemal predominant type WT (n = 53; 16.1{\%}) occurred more frequently in older children than non-blastemal type WT (n = 225), and was especially frequent in female patients registered in the JWiTS trials. No significant difference in 10 years RFS and OS (78.8{\%} vs 84.5; P = 0.201) or in 10 years RFS and OS (89.3{\%} vs 93.5; P = 0.45) was seen between pre-chemotherapy blastemal predominant type and non-blastemal type WT. Conclusions: Relapse-free survival and OS are not significantly different between pre-chemotherapy blastemal predominant type and non-blastemal type WT.",
keywords = "blastemal component, blastemal predominant type, pediatric, renal tumor, Wilms tumor",
author = "Tsugumichi Koshinaga and Tetsuya Takimoto and Hajime Okita and Yukichi Tanaka and Eisuke Inoue and Takaharu Oue and Miwako Nozaki and Kunihiko Tsuchiya and Masayuki Haruta and Yasuhiko Kaneko and Masahiro Fukuzawa",
year = "2019",
month = "4",
day = "1",
doi = "10.1111/ped.13811",
language = "English",
volume = "61",
pages = "351--357",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Blastemal predominant type Wilms tumor in Japan

T2 - Japan Children's Cancer Group

AU - Koshinaga, Tsugumichi

AU - Takimoto, Tetsuya

AU - Okita, Hajime

AU - Tanaka, Yukichi

AU - Inoue, Eisuke

AU - Oue, Takaharu

AU - Nozaki, Miwako

AU - Tsuchiya, Kunihiko

AU - Haruta, Masayuki

AU - Kaneko, Yasuhiko

AU - Fukuzawa, Masahiro

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: Persistence of blastemal components after chemotherapy is a marker of poor outcome in Wilms tumor (WT). Recent reports from local Japanese areas have described pre-chemotherapy blastemal predominant type WT to also be a risk factor for relapse. The significance, however, of blastemal predominant WT remains to be evaluated in a larger study. This study retrospectively evaluated the prognostic significance of pre-chemotherapy blastemal predominant type WT in the Japan Wilms tumor Study (JWiTS) trials. Methods: The JWiTS trial (1996–2013) was a prospective, single-arm study. The outcomes of blastemal predominant type WT were retrospectively evaluated compared with non-blastemal type WT excluding anaplasia between 1996 and 2013. Relapse-free survival (RFS) and overall survival (OS) were estimated. Results: Of 319 primary renal tumors diagnosed by the central pathology review system, advanced stage of pre-chemotherapy blastemal predominant type WT (n = 53; 16.1%) occurred more frequently in older children than non-blastemal type WT (n = 225), and was especially frequent in female patients registered in the JWiTS trials. No significant difference in 10 years RFS and OS (78.8% vs 84.5; P = 0.201) or in 10 years RFS and OS (89.3% vs 93.5; P = 0.45) was seen between pre-chemotherapy blastemal predominant type and non-blastemal type WT. Conclusions: Relapse-free survival and OS are not significantly different between pre-chemotherapy blastemal predominant type and non-blastemal type WT.

AB - Background: Persistence of blastemal components after chemotherapy is a marker of poor outcome in Wilms tumor (WT). Recent reports from local Japanese areas have described pre-chemotherapy blastemal predominant type WT to also be a risk factor for relapse. The significance, however, of blastemal predominant WT remains to be evaluated in a larger study. This study retrospectively evaluated the prognostic significance of pre-chemotherapy blastemal predominant type WT in the Japan Wilms tumor Study (JWiTS) trials. Methods: The JWiTS trial (1996–2013) was a prospective, single-arm study. The outcomes of blastemal predominant type WT were retrospectively evaluated compared with non-blastemal type WT excluding anaplasia between 1996 and 2013. Relapse-free survival (RFS) and overall survival (OS) were estimated. Results: Of 319 primary renal tumors diagnosed by the central pathology review system, advanced stage of pre-chemotherapy blastemal predominant type WT (n = 53; 16.1%) occurred more frequently in older children than non-blastemal type WT (n = 225), and was especially frequent in female patients registered in the JWiTS trials. No significant difference in 10 years RFS and OS (78.8% vs 84.5; P = 0.201) or in 10 years RFS and OS (89.3% vs 93.5; P = 0.45) was seen between pre-chemotherapy blastemal predominant type and non-blastemal type WT. Conclusions: Relapse-free survival and OS are not significantly different between pre-chemotherapy blastemal predominant type and non-blastemal type WT.

KW - blastemal component

KW - blastemal predominant type

KW - pediatric

KW - renal tumor

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=85064503622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064503622&partnerID=8YFLogxK

U2 - 10.1111/ped.13811

DO - 10.1111/ped.13811

M3 - Article

VL - 61

SP - 351

EP - 357

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 4

ER -